Vera Therapeutics Rises as Investors Focus on TRUTAKNA Launch and Conference Visibility

Vera Therapeutics (VERA) is up 4.4% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver appears to be continued investor interest in Vera’s newly launched kidney disease drug TRUTAKNA and added visibility from management’s healthcare conference appearance on September 15, 2026. There does not appear to be a separate major same-day press release, so part of the move could also reflect traders positioning around launch execution and future full-approval milestones.

Details:

TRUTAKNA, Vera’s atacicept therapy, received U.S. accelerated approval on July 7, 2026 for adults with primary IgA nephropathy at risk for disease progression, turning Vera into a commercial-stage company.

In its August 10, 2026 business update, Vera highlighted the accelerated approval and commercial launch of TRUTAKNA as transformative milestones, which likely kept attention on early launch traction.

Vera previously announced that management would present at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, creating a potential catalyst for renewed investor interest.

The company’s recent filings also continue to frame TRUTAKNA as the core value driver, with future development and confirmatory work still important for the longer-term story.

Sources:

Vera Therapeutics, SEC, FDA

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$VERA Insider Trading Activity

$VERA insiders have traded $VERA stock on the open market 12 times in the past 6 months. Of those trades, 0 have been purchases and 12 have been sales.

Here’s a breakdown of recent trading of $VERA stock by insiders over the last 6 months:

MARSHALL FORDYCE (PRESIDENT AND CEO) has made 0 purchases and 12 sales selling 124,701 shares for an estimated $4,998,396.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive VERA Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$VERA Hedge Fund Activity

We have seen 124 institutional investors add shares of $VERA stock to their portfolio, and 125 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

MORGAN STANLEY added 2,430,699 shares (+659.2%) to their portfolio in Q2 2026, for an estimated $104,301,294
LOGOS GLOBAL MANAGEMENT LP added 2,200,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $94,401,999
VESTAL POINT CAPITAL, LP removed 1,368,159 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $58,707,702
HOLOCENE ADVISORS, LP removed 1,307,393 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $50,864,124
POINT72 ASSET MANAGEMENT, L.P. removed 1,170,162 shares (-96.6%) from their portfolio in Q2 2026, for an estimated $50,211,651
TRI LOCUM PARTNERS LP removed 805,689 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $31,345,330
STATE STREET CORP added 785,148 shares (+23.3%) to their portfolio in Q2 2026, for an estimated $33,690,700

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$VERA Analyst Ratings

Wall Street analysts have issued reports on $VERA in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

B of A Securities issued a "Buy" rating on 07/07/2026

To track analyst ratings and price targets for $VERA, check out Quiver Quantitative's $VERA forecast page.

$VERA Price Targets

Multiple analysts have issued price targets for $VERA recently. We have seen 6 analysts offer price targets for $VERA in the last 6 months, with a median target of $77.0.

Here are some recent targets:

Arthur He from HC Wainwright & Co. set a target price of $125.0 on 07/08/2026
Vamil Divan from Guggenheim set a target price of $76.0 on 07/08/2026
Laura Chico from Wedbush set a target price of $35.0 on 07/08/2026
Ritu Baral from TD Cowen set a target price of $78.0 on 07/08/2026
Dina Ramadane from B of A Securities set a target price of $70.0 on 07/07/2026
Gavin Clark-Gartner from Evercore ISI Group set a target price of $91.0 on 05/15/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.